About Asamedic

From a Norwegian idea to an international cardiovascular opportunity.

Asamedic was founded to make emergency-care preparation more practical, more accessible and more ready for real-world use.

Our purpose

Practical innovation for emergency cardiovascular care.

Asamedic is a Norwegian pharmaceutical company focused on developing and commercialising Coxor®, its lead pharmaceutical asset.

The company combines product development, regulatory execution, manufacturing relationships and commercial partnerships to move the asset from innovation to market.

Milestones

The journey so far.

2013–15

Asamedic was founded and commenced full operations around the development of a new emergency ASA format.

2019–21

Marketing authorisation work progressed through a European DCP, culminating in approval and OTC status in the first markets.

2022

The Coxor® study was published in a peer-reviewed journal, strengthening the scientific foundation of the product.

2023

Coxor® launched in Norway, creating the company’s first commercial foundation.

2024–26

Asamedic moved into a broader international phase with licensing outreach, partner development and market execution.

Leadership & governance

Seasoned leadership for disciplined execution.

The team combines pharmaceutical operations, finance, regulatory affairs, commercialisation and cardiovascular expertise.

Asamedic is led by an experienced management team and supported by a board with pharmaceutical, cardiovascular, entrepreneurial and governance expertise.